Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 2Brain Neoplasms 2Primary Central Nervous System Lymphoma (PCNSL) 1Neurologic Manifestations 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Ependymoma 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 10Temozolomide 8Radiotherapy 6Magnetic Resonance Spectroscopy 6Cisplatin 6Filgrastim 5Etoposide 5Carboplatin 5Vincristine 4sargramostim 3Thiotepa 3Melphalan 3Carmustine 3Automobiles 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3fludarabine 2antineoplaston AS 2-1 2antineoplaston A10 2aldesleukin 2Thalidomide 2Paclitaxel 2Irinotecan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Eflornithine 2Donepezil 2Biopsy 2Bevacizumab 2veliparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × ibrutinib × CNS × Clear all
NCT05106296 2026-01-09

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Augusta University

Phase 1 Recruiting
37 enrolled
CNS

Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡